We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current VX1 market cap is 121.49B. The company's latest EPS is USD -2.0858 and P/E is -245.34.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 6.21B | 7.58B | 8.99B | 9.92B | 11.02B |
| Operating Income | 2.86B | 2.78B | 4.31B | 3.83B | -232.9M |
| Net Income | 2.71B | 2.34B | 3.32B | 3.57B | -535.6M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 11.75B | 13.43B | 18.15B | 22.73B | 22.53B |
| Total Liabilities | 3.06B | 3.33B | 4.24B | 5.15B | 6.12B |
| Total Equity | 8.69B | 10.1B | 13.91B | 17.58B | 16.41B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 3.25B | 2.64B | 4.13B | 3.54B | -492.6M |
| Investing | 99.39M | -340.9M | -321.1M | -3.14B | -3.77B |
| Financing | -505.28M | -1.48B | -67.7M | -562.2M | -1.49B |
| Market Cap | 121.49B |
| Price to Earnings Ratio | -245.34 |
| Price to Sales Ratio | 11.92 |
| Price to Cash Ratio | 28.76 |
| Price to Book Ratio | 8.01 |
| Dividend Yield | - |
| Shares Outstanding | 256.79M |
| Average Volume (1 week) | 332 |
| Average Volume (1 Month) | 550 |
| 52 Week Change | 23.09% |
| 52 Week High | 490.00 |
| 52 Week Low | 355.00 |
| Spread (Intraday) | 3.2 (0.67%) |
| Company Name | Vertex Pharmac Dl 01 |
| Address |
50 northern avenue boston, massachusetts 02210 |
| Website | https://www.vrtx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
